Loading…
Manufactures specialty pharmaceutical and fine chemical intermediates, including fluorinated and iodine-based compounds, for global drugmakers.
Manufactures specialty pharmaceutical and fine chemical intermediates, including fluorinated and iodine-based compounds, for global drugmakers.
In one line: A niche Indian pharma-intermediate chemical maker.
Moat: narrow (process know-how, regulatory licence). Specialized fluorination/iodination chemistry capability is not widely replicated by peers.
Headquarters: Ahmedabad, India · Employees: 1,713
Size Acutaas Chemicals (ACUTAAS.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $3.28B, the 271st largest of 1,058 India companies the cockpit tracks. Shares closed at ₹3,787 on 6 Nov 2026.
Performance Over six months the shares gained 38.9%, against +2.0% for the median peer and 0.0% for the India market (cap-weighted) — 2nd highest of 20 in its peer set.
Growth Revenue grew 45.2% over the last twelve months (peer median +13.3%); the operating margin is 36.5% (peer median 12.6%).
Valuation It trades at 61.8× forward earnings against a peer median of 21.4× (2nd most expensive of 15).
Capital Return on invested capital runs 15.9 points above its cost of capital (9.8% WACC).
Next results Next results expected around 14 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹15.9B | ₹13.4B | ₹10.1B | ₹7.17B | ₹6.17B |
| Revenue growth | — | +33% | +40% | +16% | — |
| Gross profit | ₹7.68B | ₹5.31B | ₹2.73B | ₹1.58B | ₹1.60B |
| EBITDA | ₹6.23B | ₹4.84B | ₹2.34B | ₹1.30B | ₹1.25B |
| Net income | ₹4.39B | ₹3.56B | ₹1.59B | ₹428M | ₹833M |
| Free cash flow | n/a | -₹285M | -₹717M | -₹1.93B | -₹311M |
| Capital expenditure | n/a | ₹3.28B | ₹1.95B | ₹3.15B | ₹964M |
| Total debt | ₹151M | ₹356M | ₹129M | ₹2.17B | ₹36.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Acutaas Chemicals ACUTAAS.NS | $3.28B | +39% | +45% | 36% | 61.8× | n/a |
| Navin Fluorine International NAVINFLUOR.NS | $4.89B | +27% | +46% | 30% | 45.6× | 34.0% |
| Srf SRF.NS | $7.67B | -11% | +20% | 19% | 30.3× | 25.2% |
| Neogen Chemicals NEOGEN.NS | $809M | +47% | +27% | 14% | 109.3× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ACUTAAS.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +19.3% | +1.2% | 2nd highest of 21 |
| 6-month return | +38.9% | +2.0% | 2nd highest of 20 |
| Distance from 52-week high | -6.4% | -25.8% | 4th highest of 21 |
| Revenue growth (TTM) | +45.2% | +13.3% | 5th highest of 19 |
| Operating margin | 36.5% | 12.6% | highest of 19 |
| Forward P/E | 61.8× | 21.4× | 2nd most expensive of 15 |
| ROIC minus cost of capital | +15.9 pp | +3.9 pp | 2nd highest of 16 |
| EV / EBITDA | 49.4× | 24.3× | 2nd most expensive of 9 |
| Net debt / EBITDA | -0.5× | 0.7× | 5th least indebted of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Acutaas Chemicals ACUTAAS.NS | India | $3.28B | +39% | +45% | 36% | 61.8× | n/a | n/a |
| China Medical System 0867.HK | Hong Kong | $3.30B | -16% | +15% | 20% | 10.9× | 2.9% | +2.7% |
| China National Medicines 600511.SS | China | $3.31B | +2% | +3% | 4% | 10.7× | -9.8% | +5.4% |
| Viridian Therapeutics VRDN | United States | $3.23B | +72% | -63% | -1,781% | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.35B | +19% | +26% | 13% | n/a | 56.9% | +4.2% |
| Arcutis Biotherapeutics ARQT | United States | $3.21B | +21% | +76% | 7% | 37.9× | 48.9% | +367.3% |
| Tasly Pharmaceutical 600535.SS | China | $3.20B | -5% | -4% | 19% | 16.5× | -7.6% | -9.6% |
| Piramal Pharma PPLPHARMA.NS | India | $3.37B | +30% | +9% | 3% | 159.9× | n/a | n/a |
| Tarsus Pharmaceuticals TARS | United States | $3.38B | +12% | +86% | -10% | n/a | 31.9% | +159.5% |
| Chengdu Kanghong Pharmaceutical 002773.SZ | China | $3.18B | -7% | -11% | 24% | 21.3× | -2.2% | +7.0% |
| Shanghai Henlius Biotech 2696.HK | Hong Kong | $3.41B | -37% | +33% | 12% | 23.8× | 15.2% | +61.4% |
| Viking Therapeutics VKTX | United States | $3.42B | -17% | n/a | n/a | n/a | n/a | n/a |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.47B | +2% | +3% | 19% | 19.6× | -2.2% | +12.0% |
| Hybio Pharmaceutical 300199.SZ | China | $3.08B | +16% | +70% | 31% | 51.4× | 40.1% | +6.1% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| IDEAYA Biosciences IDYA | United States | $3.02B | +10% | -83% | -1,267% | n/a | n/a | n/a |
| Betta Pharmaceuticals 300558.SZ | China | $3.01B | -9% | +16% | 11% | 44.2× | 25.2% | +14.0% |
| Suzhou Zelgen Biopharmaceuticals 688266.SS | China | $3.60B | -13% | +136% | 29% | 43.4× | 20.5% | +98.4% |
| Simcere Pharmaceutical 2096.HK | Hong Kong | $3.63B | -7% | +27% | 18% | 14.3× | -2.8% | +10.6% |
| Organon & OGN | United States | $3.64B | +4% | -3% | 20% | 4.0× | -4.5% | -1.0% |
| ACADIA Pharmaceuticals ACAD | United States | $3.66B | -5% | +12% | 8% | 21.5× | 16.7% | +19.4% |